Free Trial
NASDAQ:ATHE

Alterity Therapeutics (ATHE) Stock Price, News & Analysis

Alterity Therapeutics logo
$5.00 -0.03 (-0.50%)
Closing price 03:57 PM Eastern
Extended Trading
$5.00 -0.01 (-0.20%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alterity Therapeutics Stock (NASDAQ:ATHE)

Key Stats

Today's Range
$4.97
$5.04
50-Day Range
$3.84
$6.55
52-Week Range
$1.00
$7.00
Volume
3,639 shs
Average Volume
215,055 shs
Market Capitalization
$44.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Moderate Buy

Company Overview

Alterity Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

ATHE MarketRank™: 

Alterity Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 530th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alterity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Alterity Therapeutics has received no research coverage in the past 90 days.

  • Read more about Alterity Therapeutics' stock forecast and price target.
  • Price to Book Value per Share Ratio

    Alterity Therapeutics has a P/B Ratio of 4.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.96% of the float of Alterity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Alterity Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alterity Therapeutics has recently decreased by 9.16%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Alterity Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Alterity Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.96% of the float of Alterity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Alterity Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alterity Therapeutics has recently decreased by 9.16%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Alterity Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Alterity Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Alterity Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.14% of the stock of Alterity Therapeutics is held by institutions.

  • Read more about Alterity Therapeutics' insider trading history.
Receive ATHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATHE Stock News Headlines

Alterity Therapeutics (NASDAQ:ATHE) Stock Price Up 1.6% - Still a Buy?
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
Alterity Therapeutics highlighted at MSA Congress
See More Headlines

ATHE Stock Analysis - Frequently Asked Questions

Alterity Therapeutics' stock was trading at $3.31 at the start of the year. Since then, ATHE shares have increased by 51.2% and is now trading at $5.0050.

Alterity Therapeutics's stock reverse split on Monday, January 9th 2023.The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Alterity Therapeutics' top institutional investors include Greenleaf Trust (0.19%).

Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include NVIDIA (NVDA), GE Aerospace (GE), Broadcom (AVGO), Meta Platforms (META), Dorian LPG (LPG), CymaBay Therapeutics (CBAY) and

Company Calendar

Today
8/27/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATHE
CIK
1131343
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$12.00
Potential Upside/Downside
+137.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.84
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.04 per share
Price / Book
4.86

Miscellaneous

Outstanding Shares
8,870,000
Free Float
5,427,000
Market Cap
$44.84 million
Optionable
Not Optionable
Beta
0.67

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:ATHE) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners